Patients with primary Merkel cell carcinoma are at an increased risk of developing a secondary skin cancer vs other malignancies.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.